Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Lower risk of HF hospitalizations with ferric carboxymaltose in patients with iron deficiency, stabilized after acute HF

Literature - Jan. 14, 2021 - Ponikowski P, et al. - Lancet 2020

The AFFIRM-AHF trial showed that treatment with IV ferric carboxymaltose (FCM) in patients stabilized after acute HF and with concomitant iron deficiency reduced hospitalization due to HF.

Recommendation from FDA Advisory Committee for use of ARNI in HFpEF

News - Dec. 17, 2020

The FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 for recommending use of the ARNI sacubitril/valsartan in treatment of patients with HFpEF.

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.

In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.

High prevalence of polypharmacy in older patients hospitalized for HF

Literature - Dec. 8, 2020 - Unlu O, et al. - Circ Heart Fail 2020

Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

Dual SGLT1 and SGLT2 inhibitor reduces CV outcomes in diabetes patients in two settings

News - Nov. 19, 2020

AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD
Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

Cardiac myosin activator reduces HF hospitalization and CV death in HFrEF patients

News - Nov. 13, 2020

AHA 2020 The GALACTIC-HF trial showed that omecamtiv mecarbil reduced the primary outcome of HF hospitalization and CV death in patients with HFrEF.

IV ferric carboxymaltose reduces total HF hospitalizations in patients with acute HF and iron deficiency

News - Nov. 13, 2020

AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.

E-learning: Optimizing RAASi treatment through long-term potassium control

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Three experts in this field discuss in three separate videos: the comorbidity burden in HF patients, the effect of hyperkalemia on use of RAASi and the enabling of RAASi therapy with potassium binders.

sGC stimulator beneficial in HFrEF patients up to NT-proBNP levels of 8000 pg/mL

Literature - Nov. 10, 2020 - Ezekowitz JA, et al. - JACC Heart Fail. 2020

High-risk HFrEF patients with worsening HF and NT-proBNP levels up to 8000 pg/ml had a reduced risk of CV death and HF hospitalization when treated with vericiguat compared to placebo.

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD
Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.

Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.